FREDERICK, Maryland (Reuters) - Gilead Sciences will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the U.S. biotech's manufacturing processes, an ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. The approvals in June of two gene therapies, Elevidys and ...

Huntsman Cancer Institute adds a second compact proton therapy system, strengthening its leadership in the region Mevion Medical Systems today announced that Huntsman Cancer Institute at the ...

Capricor Therapeutics (NASDAQ:CAPR) said it has scaled up expanded capacity at its new manufacturing facility in San Diego in preparation for the anticipated launch of its cell therapy CAP-1002, with ...

(Yicai) Jan. 28 -- Chinese medical researchers have made a breakthrough in gene therapy that overcomes the limitations of ...

Huntsman Cancer Institute at the University of Utah (the U) is excited to announce the expansion of its Senator Orrin G. Hatch Proton Therapy Center, doubling its treatment capacity and increasing ...

Genenta Science has enhanced its collaboration with AGC Biologics by amending their Development and Master Services Agreement to include an exclusive GMP suite in Milan for manufacturing its cell ...